The miracle of Iressa®

Oncologist

Volumn 9, Issue 3, 2004, Pages 245-246

  Chabner, Bruce A ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BAYER 43 4009; BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; SUNITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; QUINAZOLINE DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG COST; DRUG CYTOTOXICITY; EDITORIAL; GENE MUTATION; HUMAN; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MUTATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 2942614694     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-3-245     Document Type: Editorial

References (3)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Available at: http://content.nejm.org/cgi/reprint/NEJMoa040938v1.pdf. Accessed April 29, 2004.
2. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 (in press).
3. Cohen S. Nobel lecture. Epidermal growth factor. Biosci Rep 1986;6:1017-1028.